Description

Introducing Gedomet-PG1 Bilayer Tablets: Comprehensive Diabetes Management

– Triple Action Formula: Gedomet-PG1 tablets combine Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg) in a bilayer format, offering comprehensive control of blood sugar levels for individuals with type 2 diabetes.

– Glucose Regulation: Glimepiride stimulates insulin release from the pancreas, Metformin reduces glucose production in the liver and enhances insulin sensitivity in peripheral tissues, while Pioglitazone improves insulin sensitivity in muscle and adipose tissues, collectively helping to regulate blood sugar levels effectively.

– Balanced Combination: The bilayer design ensures optimal dosing of each component, providing a balanced approach to diabetes management with minimal side effects.

– Versatile Relief: Gedomet-PG1 addresses multiple aspects of type 2 diabetes, including hyperglycemia, insulin resistance, and impaired glucose tolerance, offering versatile symptom control.

– Patient-Friendly: With once-daily dosing, Gedomet-PG1 tablets promote treatment adherence, enhancing patient convenience and compliance with therapy regimens.

– Proven Efficacy: Supported by clinical research, Gedomet-PG1 provides evidence-based efficacy in managing type 2 diabetes, offering reassurance to both healthcare professionals and patients.

– Quality Assurance: Manufactured to stringent pharmaceutical standards, Gedomet-PG1 tablets ensure quality, safety, and reliability in diabetes management.